Will Trelagliptin be included in medical insurance in 2023?

Trelagliptin (Trelagliptin) is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat type 2 diabetes. Trelagliptin increases the concentration of glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) by inhibiting the activity of DPP-4 enzyme. GLP-1 is a hormone secreted by the intestines that promotes insulin release, inhibits glucagon secretion, and delays gastric emptying, thereby lowering blood sugar levels. GLP-2 promotes the growth and repair of intestinal cells and helps improve intestinal function.

Trelagliptin, as a DPP-4 inhibitor, can maintain the stable concentrations of GLP-1 and GLP-2, thereby increasing the secretion of insulin, inhibiting the increase in blood sugar, and improving intestinal function and the health of the intestinal mucosa. When using trotagliptin, you should follow your doctor's instructions and pay attention to the correct dosage and usage. Like other drugs, trotagliptin may also have some side effects and contraindications, so you need to pay close attention to your own reactions during use and communicate with your doctor in a timely manner.

As of 2023, the original drug of trolagliptin has not yet received relevant approval for marketing in China, and therefore cannot be included in the scope of medical insurance. Currently, the price of trotagliptin original drug, specification 50mg*20 tablets per box, which is currently on the market overseas, may be around RMB 1,000 (the price may fluctuate due to exchange rates). There are also generic Trelagliptin drugs produced in other countries, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 100mg*21 tablets produced by a Bangladesh pharmaceutical factory may be several hundred yuan per box (the price may fluctuate due to exchange rates). For more drug information and specific prices, please consult Yaode Medical Consultant.